|
NovaMin Technology, Inc. (NTI) is on a mission to improve the world's oral health through innovation. Oral health is a key driver of systemic health and quality of life. NTI believes that it can make a difference around the world through by partnering with leading dental and oral heathcare manufacturers around the world to add the power on NovaMin to their products. The power of NovaMin has already reached over 3 million patients and consumers in over 20 countries.
The Company has a lively, fast-paced culture based on team-work. We are based in Alachua, Florida, a suburb of Gainesville. NovaMin enjoys the cultural impact and available research resources of nearby University of Florida. Our team is made up of individuals working to make a difference every day.
|
The
Company has two areas of activity:
|
|
|
Specialty
Products...
Co-development of specialty products - used or dispensed by dental professionals - through established partnerships with leaders in the field like Sunstar-Butler, 3M/Omnii Hager-Werken and Ideco Linea Odontiatrica.
|
|
|
|
Consumer
Products...
In the consumer products field, the company is working with selected
prominent consumer product marketers on development of toothpaste and
other products that incorporate NovaMin.
|
|
The
Company has a strong management team and Board of Directors:
|
|
|
Board of Directors:
- Chris Hegele:
Chris Hegele is a partner with Intersouth Partners, where he works with both information technology and life sciences companies in Intersouth's portfolio. Chris has spent over 20 years in venture capital investing following his experience with with Arthur Andersen & Co. in its Small Business Group.
- Bannus Hudson:
Ban Hudson is a consumer goods executive. He currently is CEO of Beverages and More, a California retailer. Previously he was CEO of US Shoe Corp (a Fortune 500 company) and had a successful career at Procter & Gamble.
- Garheng Kong, MD, PhD:
Garheng is a partner at Intersouth Partners, where he focuses on the firm's life sciences portfolio. He has been a clinical scientist at Glaxo Wellcome and was actively involved in commercializing early-stage technology with the Duke University Office of Science and Technology. Garheng has led investments and has board-level involvement across most of Intersouth's life science companies.
- Randy Scott: NovaMin CEO.
- Arthur Wotiz:
Art Wotiz is a specialty chemical and medical device executive. He is currently CEO of NovaBone Products, LLC and formerly ran PCR Chemicals and Harris Specialty Chemicals, which he helped form from over a dozen mergers on 3 continents.
|
|
|
|
|